On the other hand, futibatinib received accelerated approval from the FDA to address the treatment needs of adult patients confronting previously treated, unresectable, locally advanced, or metastatic iCCA exhibiting FGFR2 fusions or other rearrangements. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.